- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04682600
The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Liver Incytes system allows for full visualization of the liver with the low cost and portability of ultrasound. It is an adjustable multi-frequency technique, which can show large areas of the organ as volumetric elasticity maps. The device uses the Shear Wave Absolute Vibro-Elastography (S-WAVE) method.
The primary objective of the study is to determine the relationship between the elasticity results from Liver Incytes and those of MR Elastography. In addition to stiffness measurements, the relationship between the Liver Incytes attenuation measurements and MR-PDFF will also be evaluated.
As secondary objectives, the ability of Liver Incytes to correctly stage patients using MRE as the standard (unless biopsy is available), looking specifically at the ability to measure mild and advanced fibrosis.
In additional to performance objectives, the safety, tolerability and usability of the device will be assessed.
This is a prospective, open label, validation study of the Liver Incytes system in comparison to MR results (as gold standard) in patients with liver disease or suspected liver disease. Approximately 100 subjects may be enrolled in this study which will take place at clinical centers across Canada and the United States. Study participants should be distributed primarily across the 4 stages of fibrosis, with secondary consideration of the three stages of steatosis.
The study is comprised of: Screening Period (up to 28 days) and Data Collection Period. There are no safety follow-up visits in this study.
- Screening Period (-28 days to Prior to Imaging (Fibroscan, Liver Incytes, MRE)): during the screening phase, participants will provide written informed consent before undergoing procedures to determine study eligibility.
- Data Collection Period (variable duration): Study participants will attend a study visit on Day 1 and may attend an optional visit within 28 days of the initial/Day 1 visit.
The total duration of study participation will vary from approximately 2 weeks to approximately 8 weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults, 19-75 years old
- Healthy volunteers or Patients with evidence of NAFLD such as one of the following:
Previous liver biopsy consistent with NAFLD OR
Evidence of hepatic steatosis on non-invasive assessment by one or more of the following criteria:
- Abdominal ultrasound within 12 months
- MRI-PDFF (greater than 12%) within 12 month
- FibroScan CAP score > 230 dB/m within 12 months OR At least 2 criteria for metabolic syndrome and increased stiffness on FibroScan (>8kPa) within 12 months
- Able to understand the informed consent form, study procedures and willing to participate in study
- If female and of child bearing potential, must agree to practice a highly effective contraception method.
Exclusion Criteria:
Active viral hepatitis
a. Patients with cured HCV (those with history of treatment and have Sustained Viral Response for 12 weeks (SVR12)) or controlled HBV with no viral detected for more than 6 months are eligible
- Decompensated cirrhosis (history of ascites, encephalopathy, or variceal bleeding)
- ALT or AST > 5 x ULN on historical blood work within the past 3 months
- BMI greater than 40 kg/m2 (or using cutoff based on MRI)
- Other known causes of chronic liver disease
- Individuals with history of persistent ethanol abuse (alcohol consumption > 20g etoh/day for women, > 40 g etoh/day for men)
- Individuals with surgically removed gallbladder
- Pregnant or planning to become pregnant while enrolled in this study
- Other conditions which would exclude patients from entering an MRI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Open-label
Volunteers who have agreed to participate in the study will have their liver scanned using the FibroScan, VE (Liver Incytes System) and MRE techniques.
|
The Liver Incytes System uses the Shear Wave Absolute Vibro-Elastrography (S-WAVE) method.
The imaging procedure of the Liver Incytes system is similar to a traditional ultrasound scanning procedure or FibroScan, in which the patient is asked to lie supine on an examination bed, with the operator seated next to them.
A vibration source is placed under the patient, between the patient and the bed to induce shear waves in the liver.
Ultrasound imaging through the patient ribs is used to track the displacements of these waves.
Through tracking of the displacements, the shear wave velocity and tissue stiffness can be calculated.
The use of volumetric multi-frequency imaging increases the amount of liver scanned
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Elasticity measurements comparison between Liver Incytes MR Elastography
Time Frame: 12 months
|
Elasticity measurements (kPa) from the Liver Incytes system and the MR system will be compared to determined whether the reported stiffness of the tissue (mean and 95% confidence intervals) are equivalent by concordance correlation coefficient and 95% confidence intervals.
|
12 months
|
Determination of Liver Incytes' discriminatory ability of liver stiffness as measured by fibrosis staging
Time Frame: 12 months
|
Liver Incytes liver stiffness values will be compared to values obtained using MRE to determine the cutoff values for the Liver Incytes System for each level of fibrosis staging.
For each stage of fibrosis as defined by MRE, Area Under the Receiver Operating Curve (AUROC) for Liver Incytes elasticity will be calculated and the cutoff maximizing the sensitivity and specificity will be determined.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Attenuation measurements comparison between the Liver incytes System and MRI Proton Density Fat Fraction
Time Frame: 12 months
|
Attenuation measurements (dB/m) from the Liver Incytes System and MRI proton density fat fraction will be compared to determine whether they are equivalent by concordance correlation coefficient and 95% confidence intervals
|
12 months
|
Comparison between Liver Incytes' and FibroScan's fibrosis staging capabilities
Time Frame: 12 months
|
Compare the discriminatory ability of Liver Incytes' and FibroScan's elasticity (kPa) measurements in determining different stages of fibrosis using MRE as gold standard. For each stage of fibrosis, a Receiver Operating Curve will be constructed using the corresponding FibroScan measurements, and the Area Under the Receiver Operating Curve (AUROC) will be compared to the result from Liver Incytes. |
12 months
|
Comparison between Liver Incytes' and FibroScan's steatosis staging capabilities
Time Frame: 12 months
|
Compare the discriminatory ability of Liver Incytes' and FibroScan's attenuation measurements (dB/m) in determining different stages of steatosis using MRE as gold standard. For each stage of steatosis, a Receiver Operating Curve will be constructed using the corresponding FibroScan measurements, and the Area Under the Receiver Operating Curve (AUROC) will be compared to the result from Liver Incytes. |
12 months
|
Incidence of and Device Deficiencies
Time Frame: 12 months
|
The frequency of device deficiencies and failures will be described based on events reported
|
12 months
|
Incidence of Adverse Events
Time Frame: 12 Months
|
Descriptive statistics including frequency and severity of all reported adverse events.
|
12 Months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of cases in which FibroScan may overestimate or underestimate liver stiffness
Time Frame: 12 months
|
The elasticity (kPa) output from Liver Incytes, FibroScan, and MRE/PDFF will be used to identify and compare the cases in which the measurements do not match.
Descriptive statistics regarding the populations in which the FibroScan systematically over or underestimates compared to MRE/MRI PDFF and the corresponding results from Liver Incytes
|
12 months
|
Identification of cases in which FibroScan may overestimate or underestimate fat content
Time Frame: 12 months
|
The attenuation (dB/m) output from Liver Incytes, FibroScan, and MRE/PDFF will be used to identify and compare the cases in which the measurements do not match.
Descriptive statistics regarding the populations in which the FibroScan systematically over or underestimates compared to MRE/MRI PDFF and the corresponding results from Liver Incytes
|
12 months
|
Liver Incytes System User Experience Survey
Time Frame: 12 months
|
Descriptive statistics such as N, proportion, mean, median, SD, and range will be calculated for the composite score of the User Experience Survey, based on the modified System Usability Scale (mSUS). Descriptive statistics such as N, proportion, mean, median, SD, and range will be calculated for each question in the User Experience Survey and Liver Incytes Session Questionnaire. The modified SUS yields a single number representing a composite measure of the overall usability of the system being studied. It is composed of 10 questions, 5 positive in nature, and 5 negative. The score ranges from 0 to 6 and higher scores may mean a better or worse outcome depending on whether the question is positive or negative. |
12 months
|
Liver Incytes System Inter-user Elasticity Variability
Time Frame: 12 months
|
For subjects who participate in the optional additional visit, inter-user device variability, if applicable, will be assessed by comparing reported elasticity (kPa).
Variance for each measurement will be calculated.
|
12 months
|
Liver Incytes System Inter-user Attenuation Variability
Time Frame: 12 months
|
For subjects who participate in the optional additional visit, inter-user device variability, if applicable, will be assessed by comparing reported attenuation (dB/m).
Variance for each measurement will be calculated.
|
12 months
|
Liver Incytes System Intra-Subject Variability
Time Frame: 12 months
|
For subjects who participate in the optional additional visit, intra-subject variability will be assessed by comparing reported elasticity (kPa).
Variance for each measurement will be calculated.
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SI-CLIN-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Fibroses
-
Olympus Corporation of the AmericasGeisinger ClinicCompleted
-
Seoul National University HospitalCompletedLiver Fibroses | Liver MassKorea, Republic of
-
Vilnius UniversityCompletedLiver Cirrhosis | Liver FibrosesLithuania
-
Seoul National University HospitalSamsung MedisonCompleted
-
University of MichiganChildren's Hospital Medical Center, CincinnatiCompletedLiver FibrosesUnited States
-
Raymond ChungUniversity of Texas Southwestern Medical CenterRecruitingCirrhosis | Liver FibrosesUnited States
-
Chinese University of Hong KongRecruiting
-
SuperSonic ImagineUniversity of BonnCompleted
-
Children's Hospital Medical Center, CincinnatiTerminated
Clinical Trials on Liver Incytes System
-
Indiana UniversitySonic IncytesTerminatedNAFLD | NASH - Nonalcoholic SteatohepatitisUnited States
-
Washington University School of MedicineTerminated
-
Sohag UniversityEnrolling by invitation
-
Bridge to Life Ltd.Active, not recruitingLiver Failure | End Stage Liver DIseaseUnited States
-
University of ZurichUnknownDeath | ComplicationSwitzerland
-
Seoul National University HospitalGuerbetActive, not recruitingLiver Cirrhosis | Hepatocellular Carcinoma | Chronic HepatitisKorea, Republic of
-
Rutgers, The State University of New JerseyRecruitingIntrahepatic Cholangiocarcinoma | Cholangiocarcinoma, IntrahepaticUnited States
-
The Cleveland ClinicCompleted